CN114989190A - Macrolide compound kongjuemycins and preparation method and application thereof - Google Patents
Macrolide compound kongjuemycins and preparation method and application thereof Download PDFInfo
- Publication number
- CN114989190A CN114989190A CN202210418878.1A CN202210418878A CN114989190A CN 114989190 A CN114989190 A CN 114989190A CN 202210418878 A CN202210418878 A CN 202210418878A CN 114989190 A CN114989190 A CN 114989190A
- Authority
- CN
- China
- Prior art keywords
- compound
- spectrum
- macrolide compound
- fraction
- eluted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 83
- 239000003120 macrolide antibiotic agent Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 10
- 241001464398 Pseudonocardia kongjuensis Species 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 15
- 230000004151 fermentation Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 239000003429 antifungal agent Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000287 crude extract Substances 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 241000190150 Bipolaris sorokiniana Species 0.000 claims description 4
- 241001529387 Colletotrichum gloeosporioides Species 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 241001115351 Physalospora Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 229940041033 macrolides Drugs 0.000 abstract description 2
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 229940125782 compound 2 Drugs 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 229940125898 compound 5 Drugs 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 9
- 238000005100 correlation spectroscopy Methods 0.000 description 9
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001374 post-anti-biotic effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a macrolide compound kongjuememycins, a preparation method and application thereof. The structure of the macrolide compound is shown in any one of formula (I). The invention separates the anti-virus from the strain P.kongjuensis SCSIO 114571-8 macrolides with fungal activity, and therefore these compounds can be used for the preparation of antifungal drugs.
Description
The technical field is as follows:
the invention belongs to the field of industrial microorganisms, and particularly relates to novel kongjuememycins compounds 1-8 as well as a preparation method and application thereof.
Background art:
macrolide compounds are antibiotics with various structures and broad-spectrum antibacterial activity, and are clinically important anti-infective drugs, such as erythromycin, roxithromycin, azithromycin and the like. In the face of the current increasingly clinical drug-resistant bacteria, the discovery and the modification of new macrolide antibiotics become an important strategy, and have great significance for resisting the threat of the post-antibiotic era.
The invention content is as follows:
the first object of the present invention is to provide 8 novel macrolides kongjuememycins (1-8).
The invention relates to 8 novel macrolide compounds kongjuuemycins (1-8), the structure of which is shown in formula (I):
wherein, the compound 2 is kongjuememycin B1, and R is CH 2 CH 2 CH 3 (ii) a The compound 3 is kongjuememycin B2, and R is CH (CH) 3 ) 2 (ii) a The compound 4 is kongjuememycin B3, and R is CH 2 CH 2 CH 2 CH 3 (ii) a The compound 5 is kongjuememycin C1, and R is CH 2 CH 3 (ii) a The compound 6 is kongjuememycin C2, and R is CH 2 CH 2 CH 3 (ii) a The compound 7 is kongjuememycin C3, and R is CH (CH) 3 ) 2 (ii) a The compound 8 is kongjuememycin C4, and R is CH 2 CH 2 CH 2 CH 3 。
The second purpose of the invention is to provide the application of the compound in preparing antifungal medicines.
An antifungal agent contains the macrolide compound kongjueumycins as an active ingredient.
The antifungal agent is an anti-Colletotrichum gloeosporioides Penz, physiosporiicola Nose and/or Bipolaris sorokiniana.
A third object of the present invention is to provide a method for preparing a compound kongjuememycins (1-8), which is characterized by comprising the steps of: the compound kongjueumycins (1-8) was isolated from a fermentation culture of Pseudomonas kongjueuensis SCSIO 11457.
Preferably, the method comprises the following specific steps:
performing fermentation culture on the strain P.kongjuensis SCSIO 11457 by using an N4 culture medium, putting macroporous resin in a culture system, collecting the macroporous resin and mycelium after culture, and eluting the macroporous resin by using acetone; leaching mycelium with acetone, ultrasonically crushing, recovering organic solvent, extracting the rest water phase with ethyl acetate, and recovering ethyl acetate to obtain crude extract;
separating the crude extract by normal phase silica gel column chromatography, performing gradient elution with chloroform/methanol as eluent, performing gradient elution from 100/0, 9/1, 4/1, 2/1, 1/1 and 0/100 at v/v, separating fraction Fr2 eluted with chloroform/methanol 9/1v/v by reverse phase silica gel column chromatography, and purifying the eluted fraction to obtain compounds 1 and 2-4; separating fraction Fr3-4 eluted with chloroform/methanol 4/1 and 2/1v/v with reverse phase silica gel column chromatography, and purifying the eluted fraction to obtain compound 5-8.
Application of the strain P.kongjuensis SCSIO 11457 in preparation of compounds 1-8.
The invention separates macrolide compounds 1-8 with antifungal activity from a strain P.kongjuensis SCSIO 11457, so that the compounds can be used for preparing antifungal medicaments.
The actinomycete Pseudomonas kongjuensis SCSIO 11457 of the present invention is disclosed in the literature: secondary metabolite study of two marine-derived actinomycetes, authors: zhuangjie, Master thesis, southern Hai Marine institute of Chinese academy of sciences, 2019. This strain is also held by the applicant and is guaranteed to be provided to the public within 20 years from the filing date.
Description of the drawings:
FIG. 1 is a high performance liquid chromatogram of a fraction Fr2-7 of a fermentation extract.
High Performance Liquid Chromatography (HPLC) conditions: the chromatographic column is Phenomenex Luna C18,150mm multiplied by 4.6mm,5 mu m; the mobile phase comprises a phase A and a phase B, wherein the phase A: 10% acetonitrile/water (v/v) + 0.1% formic acid (v/v), phase B: 90% acetonitrile/water (v/v); sample introduction procedure: 5% B-80% B (0-20min), 80% B-100% B (20-21min), 100% B (21-25min), 100% B-5% B (25-26min), 5% B (26-30min), detection wavelength of 280nm, flow rate of 1 mL/min -1 . Wherein 1 represents compound 1 and 2 represents compound 2.
FIG. 2 is a high performance liquid chromatogram of a fraction Fr2-8 of the fermentation extract. The conditions for High Performance Liquid Chromatography (HPLC) were as above, wherein 3 represents compound 3 and 4 represents compound 4.
FIG. 3 is a high performance liquid chromatogram of a fraction Fr3-4-8 of the fermentation extract. High Performance Liquid Chromatography (HPLC) conditions were as above, with 6 representing compound 6, 7 representing compound 7, and 8 representing compound 8.
FIG. 4 is a high performance liquid chromatogram of a fermentation extract fraction Fr 3-4-8. High Performance Liquid Chromatography (HPLC) conditions were as above, wherein 5 represents compound 5.
FIG. 5 is a HRESIMS spectrum of Compound 1; FIG. 6 is a drawing of Compound 1 1 H-NMR spectrum; FIG. 7 is a drawing of Compound 1 13 C-NMR spectrum; figure 8 is DEPT135 spectrum of compound 1; FIG. 9 is a COSY spectrum of compound 1; FIG. 10 is an HSQC spectrum of Compound 1; FIG. 11 is H of Compound 1MBC spectrogram;
FIG. 12 is a HRESIMS spectrum of Compound 2; FIG. 13 is a photograph of Compound 2 1 H-NMR spectrum; FIG. 14 is a photograph of Compound 2 13 A C-NMR spectrum; figure 15 is the DEPT135 spectrum of compound 2; FIG. 16 is a COSY spectrum of compound 2; figure 17 is an HSQC spectrum of compound 2; FIG. 18 is an HMBC spectrum of compound 2; FIG. 19 is a ROESY spectrum of Compound 2;
FIG. 20 is a HRESIMS spectrum of Compound 3; FIG. 21 is of Compound 3 1 H-NMR spectrum; FIG. 22 is of Compound 3 13 A C-NMR spectrum; figure 23 is DEPT135 spectrum of compound 3; FIG. 24 is a COSY spectrum of compound 3; figure 25 is an HSQC spectrum of compound 3; FIG. 26 is an HMBC spectrum of compound 3;
FIG. 27 is a HRESIMS spectrum of Compound 4; FIG. 28 is of Compound 4 1 H-NMR spectrum; FIG. 29 is of Compound 4 13 A C-NMR spectrum; figure 30 is a DEPT135 spectrum of compound 4; FIG. 31 is a COSY spectrum of compound 4; FIG. 32 is an HSQC spectrum of Compound 4; FIG. 33 is an HMBC spectrum of compound 4;
FIG. 34 is a HRESIMS spectrum of Compound 5; FIG. 35 is a drawing of Compound 5 1 H-NMR spectrum; FIG. 36 is of Compound 5 13 A C-NMR spectrum; figure 37 is a DEPT135 spectrum of compound 5; FIG. 38 is a COSY spectrum of compound 5; FIG. 39 is an HSQC spectrum of Compound 5; FIG. 40 is an HMBC spectrum of compound 5; FIG. 41 is a ROESY spectrum of Compound 5;
FIG. 42 is a HRESIMS spectrum of Compound 6; FIG. 43 is of Compound 6 1 H-NMR spectrum; FIG. 44 is of Compound 6 13 A C-NMR spectrum; figure 45 is DEPT135 spectrum of compound 6; FIG. 46 is a COSY spectrum of compound 6; FIG. 47 is an HSQC spectrum of Compound 6; FIG. 48 is an HMBC spectrum of compound 6;
FIG. 49 is a HRESIMS spectrum of Compound 7; FIG. 50 is of Compound 7 1 H-NMR spectrum; FIG. 51 is of Compound 7 13 A C-NMR spectrum; figure 52 is the DEPT135 spectrum of compound 7; FIG. 53 is a COSY spectrum of compound 7; figure 54 is an HSQC spectrum of compound 7; figure 55 is the HMBC spectrum of compound 7.
FIG. 56 is a HRESIMS spectrum of Compound 8; FIG. 57 is of Compound 8 1 H-NMR spectrum; FIG. 5The 8 being a compound of formula 8 13 A C-NMR spectrum; figure 59 is a DEPT135 spectrum of compound 8; FIG. 60 is a COSY spectrum of compound 8; figure 61 is an HSQC spectrum of compound 8; figure 62 is an HMBC spectrum of compound 8.
The specific implementation mode is as follows:
the following examples are further illustrative of the present invention and are not intended to be limiting thereof.
The wild-type strain p. kongjuuensis SCSIO 11457 produced the novel compounds 1 to 8 in the N4 medium, and analysis of hresms and NMR data confirmed the structures of 8 novel compounds kongjuuemycins (1) (fig. 5 to 11), kongjuuemycins B1(2) (fig. 12 to 19), kongjuuemycins B2(3) (fig. 20 to 26), kongjuuemycins B3(4) (fig. 27 to 33), kongjuuemycins C1(5) (fig. 34 to 41), kongjuuemycins C2(6) (fig. 42 to 48), kongjuuemycins C3(7) (fig. 49 to 55) and kongjuuemycins C4(8) (fig. 56 to 62).
The following further provides examples which are intended to aid in the understanding of the present invention and are intended to be illustrative rather than limiting.
Example 1
1. Amplified fermentation culture
The strain P.kongjuensis SCSIO 11457 is activated on a 38# culture medium solid plate, then a proper amount of spores and mycelium are scraped and inoculated into 200mLN4 fermentation medium (total 60L), and the fermentation culture is obtained after culturing for 5d at the temperature of 28 ℃ and the speed of 200rpm of a shaker.
38 # Culture medium: 5.0g of malt extract powder, 4.0g of glucose, 4.0g of yeast extract powder and 30g of sea salt, adding purified water to 1L, adjusting pH to 7.0, and sterilizing.
N4 medium: 15g of soluble starch, 8g of fish peptone, 5g of bacteriological peptone, 7.5g of glycerol, CaCO 3 2g of KBr, 0.2g of sea salt, 30g of HP20 macroporous resin 5% (mass fraction, namely 50g), and purified water is added to 1L, and the pH value is 7.0. Sterilizing to obtain the product.
2. Extraction of fermentation broth
And (4) respectively collecting the HP20 macroporous resin and fermentation liquor by using a separating funnel after the fermentation culture of 5 d. Centrifuging the fermentation liquor at 3900rpm for 20min, collecting mycelia, and eluting macroporous resin with 15L acetone; the mycelia were extracted 3 times with 1L of acetone, and the cells were disrupted by sonication for 0.5h each time. And recovering the organic solvents in the two parts by using a rotary evaporator, combining the rest water, extracting for 10 times by using 1L ethyl acetate, and recovering ethyl acetate in the ethyl acetate extract by using the rotary evaporator to obtain a crude extract.
3. Isolation of the Compound
10g of crude extract of N4 medium of the above wild type strain P. kongjuensis SCSIO 11457 was dissolved in chloroform methanol (1:1, v/v), 40mL of 100-mesh silica gel was added and stirred, the mixture was packed in a column by a 1:3 dry method in a stirred silica gel (40 mL)/separation silica gel (120mL), and gradient elution was carried out using chloroform/methanol as an eluent (100/0, 9/1, 4/1, 2/1, 1/1 and 0/100, v/v, each gradient being 800mL) to obtain fractions Fr1-Fr6 in this order. Fraction Fr2 (fraction eluted with chloroform/methanol 90/10 v/v) was subjected to medium pressure reverse phase chromatography (YMC × GEL ODS-A-HG, 12nm S-50 μm) with A phase A/B ═ water/acetonitrile (v/v) according to the following procedure: 10% B (0-20min), 10% B to 60% B (20-60min), 60% B (60-90min), 60% B to 90% B (90-120min), 90% B (120-150min), and a flow rate of 20mLmin -1 Fractions Fr2-1 to Fr2-10 were obtained in this order. Fraction Fr2-7 has the target compound according to the detection result of High Performance Liquid Chromatography (HPLC) (FIG. 1), therefore fraction Fr2-7 was purified by semi-preparative high performance liquid chromatography (Phenomenex Luna C18, 250 mm. times.10.0 mm,5 μm; phase A was water, phase B was acetonitrile, volume fraction 55% of phase B was eluted at equal rate; flow rate was 2.5 mL/min; detection wavelength was 280nm) to obtain compounds kongjueymycinA (1) (Rt 22.0min) and kongjueycin B1(2) (Rt 20.0 min). Fraction Fr2-8 has the target compound according to the detection result of High Performance Liquid Chromatography (HPLC) (FIG. 2), therefore fraction Fr2-8 is purified by semi-preparative high performance liquid chromatography (Phenomenex Luna C18, 250 mm. times.10.0 mm,5 μm; phase A is water, phase B is acetonitrile, volume fraction 60% of phase B is eluted at equal rate; flow rate is 2.5 mL/min; detection wavelength is 280nm) to obtain compounds kongjueymycin B2(3) (Rt 24.0min) and kongjueymycin B3(4) (Rt 28.0 min). Fractions Fr3 and Fr4 (fractions eluted with chloroform/methanol 4/1 and 2/1 v/v) were combined and eluted by medium pressure reverse phase chromatography (YMC × GEL ODS-A-HG, 12nm S-50 μm) with phase A/B ═ water/acetonitrile (v/v) according to the following procedure: 10% B (0-20min), 10% B to 50% B (20-60min), 50% B (60-90min), 50% Bto 90% B (90-120min), 90% B (120-150min), flow rate 20mL min -1 Fractions Fr3-4-1 to Fr3-4-12 were obtained in this order. Fraction Fr3-4-8 has the target compound according to the results of High Performance Liquid Chromatography (HPLC) (FIG. 3), and therefore fraction Fr3-4-8 was purified by semi-preparative high performance liquid chromatography (Phenomenex Luna C18, 250 mm. times.10.0 mm,5 μm; phase A was water, phase B was acetonitrile, volume fraction 40% of phase B was eluted at equal rate; flow rate was 2.5 mL/min; detection wavelength was 280nm) to give the compounds kongjueymycin C2(6) (Rt 15.0min), kongjueymycin C2(7) (Rt 20.0min) and kongjueymycin C3(8) (Rt 22.0 min). Fraction Fr3-4-7 has the target compound according to the detection result of High Performance Liquid Chromatography (HPLC) (FIG. 4), therefore fraction Fr3-4-7 is purified by semi-preparative high performance liquid chromatography (Phenomenex Luna C18, 250 mm. times.10.0 mm,5 μm; phase A is water, phase B is acetonitrile, 38% volume fraction of phase B is eluted at equal rate; flow rate is 2.5 mL/min; detection wavelength is 280nm) to obtain compound kongjuememycin C4(5) (Rt ═ 20.0 min).
1. Structural identification of compounds
The structures of the compounds 1-8 are according to HRESIMS, 1 H-NMR、 13 C-NMR, DEPT135, HSQC, HMBC and COSY spectra were identified, and the nuclear magnetic data are assigned in tables 1 and 2. The spectrum of Kongjuuemycin A (1) is shown in FIGS. 5-11, the spectrum of kongjuuemycin B1(2) is shown in FIGS. 12-19, the spectrum of kongjuuemycin B2(3) is shown in FIGS. 20-26, the spectrum of kongjuuemycin B3(4) is shown in FIGS. 27-33, the spectrum of kongjuuemycin C1(5) is shown in FIGS. 34-41, the spectrum of kongjuuemycin C2(6) is shown in FIGS. 42-48, and the spectrum of kongjuuemycin C3(7) is shown in FIGS. 49-55 and the spectrum of kongjuuemycin C4(8) is shown in FIGS. 56-62.
The structural formulae of compounds 1 to 8 were thus determined as follows:
of compounds 1 to 4 of Table 1 1 H-NMR (700MHz) and 13 C-NMR (175MHz) Nuclear magnetic data
TABLE 2 preparation of compounds 5 to 8 1 H-NMR (700MHz) and 13 C-NMR (175MHz) nuclear magnetic data
EXAMPLE 2 determination of antifungal Activity of Compounds 1-8
The inhibitory activities of the compounds 1 to 8 against the 3 plant pathogenic fungi Colletotrichum gloeosporioides Penz, physiosporia piricola Nose and Bipolaris sorokiniana were determined by the microculture medium dilution method. Culturing 3 plant pathogenic fungi at 28 deg.C and 200rpm for 48h in shaking table, diluting with sterile PDB culture medium to OD (600nm) of 0.04-0.06, diluting 1000 times, and adding into 96-well plate; after addition of the sample, the aliquots were diluted to final concentrations of 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25. mu.g mL -1 3 replicates per concentration; culturing at 28 deg.C for 48-72h, measuring absorbance of each well with microplate reader, and calculating Minimum Inhibitory Concentration (MIC) of each compound, and inhibition rate (%) (1- (sample A-sample background)/(A negative control-blank control)) × 100%, inhibition rate>80% are MIC values. The results are shown in Table 3.
TABLE 3 antibacterial Activity (MIC, μ gmL) of Compounds 1-8 -1 )
Claims (8)
2. use of a macrolide compound or a pharmaceutically acceptable salt thereof according to claim 1 for the preparation of an antifungal agent.
3. The use according to claim 2, wherein the antifungal agent is an agent against Colletotrichum gloeosporioides Penz, Physiospora piricola Nose and/or Bipolaris sorokiniana.
4. An antifungal agent comprising the macrolide compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.
5. The antifungal agent of claim 4 wherein the antifungal agent is an agent against Colletotrichum gloeosporioides Penz, Physalospora piricola Nose and/or Bipolaris sorokiniana.
6. A process for preparing a macrolide compound according to claim 1, comprising the steps of: the macrolide compound is isolated from the fermentation culture of Pseudonocardia kongjuensis SCSIO 11457.
7. The method of claim 6, comprising the steps of:
performing fermentation culture on the strain P.kongjuensis SCSIO 11457 by using an N4 culture medium, putting macroporous resin in a culture system, collecting the macroporous resin and mycelium after culture, and eluting the macroporous resin by using acetone; leaching mycelium with acetone, ultrasonically crushing, recovering organic solvent, extracting the rest water phase with ethyl acetate, and recovering ethyl acetate to obtain crude extract;
separating the crude extract by normal phase silica gel column chromatography, performing gradient elution with chloroform/methanol as eluent, performing gradient elution from 100/0, 9/1, 4/1, 2/1, 1/1 and 0/100 at v/v, separating fraction Fr2 eluted with chloroform/methanol 9/1v/v by reverse phase silica gel column chromatography, and purifying the eluted fraction to obtain compounds 1 and 2-4; separating fraction Fr3-4 eluted with chloroform/methanol 4/1 and 2/1v/v by reverse phase silica gel column chromatography, and purifying the eluted fraction to obtain compound 5-8.
8. Use of the strain p. kongjuensis SCSIO 11457 for the preparation of a macrolide compound according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210418878.1A CN114989190B (en) | 2022-04-20 | 2022-04-20 | Macrolide compound kongjuemycin, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210418878.1A CN114989190B (en) | 2022-04-20 | 2022-04-20 | Macrolide compound kongjuemycin, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114989190A true CN114989190A (en) | 2022-09-02 |
CN114989190B CN114989190B (en) | 2024-02-09 |
Family
ID=83025449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210418878.1A Active CN114989190B (en) | 2022-04-20 | 2022-04-20 | Macrolide compound kongjuemycin, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114989190B (en) |
-
2022
- 2022-04-20 CN CN202210418878.1A patent/CN114989190B/en active Active
Non-Patent Citations (3)
Title |
---|
IMRAN KHAN,ET AL.: "Cylindromicin from Arctic-Derived Fungus Tolypocladium sp. SCSIO 40433", 《MOLECULES》, vol. 26, pages 1080 * |
JIE LI,ET AL.: "Detection of polyketide synthase and nonribosomal peptide synthetase biosynthetic genes from antimicrobial coral- associated actinomycetes", 《ANTONIE VAN LEEUWENHOEK》, vol. 106, pages 623 - 635, XP035387262, DOI: 10.1007/s10482-014-0233-1 * |
ZHUANGJIE FANG,ET AL.: "A new uridine derivative and a new indole derivative from the coral-associated actinomycete Pseudonocardia sp. SCSIO 11457", 《NATURAL PRODUCT RESEARCH》, vol. 35, no. 2, pages 188 - 194 * |
Also Published As
Publication number | Publication date |
---|---|
CN114989190B (en) | 2024-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115490661B (en) | Antioxidant active compound in mangrove-derived fungi and preparation method thereof | |
CN108753627A (en) | A kind of marine aspergillus source oxa- anthraquinone analog compound and preparation method thereof and the application in preparing antitumor agent | |
CN106432168B (en) | The anti-vibrios reactive compound and preparation method thereof in mangrove cusp sea lotus endogenetic fungus source | |
CN115724816B (en) | Chromone crystal form in mangrove-derived fungi and preparation and application thereof | |
CN108441427B (en) | Arthriospora fungi and pyridone alkaloid compound produced by same | |
CN114989190A (en) | Macrolide compound kongjuemycins and preparation method and application thereof | |
CN111892574A (en) | Atypical keratinocyte compounds and preparation method and application thereof | |
CN106432169B (en) | A kind of active isocoumarin class compound of anti-vibrios and its crystal | |
CN115109023A (en) | Macrolide compound FWYZ52-A, and fermentation strain, fermentation method and application thereof | |
CN111808112B (en) | Pratensilin D compound and preparation and application thereof | |
US10119158B2 (en) | Process for the preparation of fidaxomicin | |
CN110872338B (en) | Indole diterpenoid compound and preparation method and application thereof | |
Martin et al. | Isolation, purification and properties of the hexaene macrolides candihexin I and candihexin II | |
CN113396214A (en) | Method for producing nigericin from streptomyces sp.mcc-0151 | |
CN107973803B (en) | Seven-membered lactonofuran derivative and preparation method and application thereof | |
AU2016362540B2 (en) | Antibiotic FIIRV 104/18 complex and the isolated individual factors thereof | |
CN111285828B (en) | Compound proximicin and preparation method and application thereof | |
EP2886640A1 (en) | Process for isolation of milbemycins A3 and A4 | |
CN106957216B (en) | Preparation method and antifungal application of antifungal compound | |
CN109320527A (en) | Deer chromomycin (cervinomycin) B1, B2, B3, B4 and its production method and application | |
CN115504990B (en) | Sugar-spiro-macrolide compound FW-5-39 and preparation method and application thereof | |
KR20010039119A (en) | Process for the purification of Avermectin | |
CN108623644B (en) | Paulomycin derivatives and preparation method and application thereof | |
CN115626942A (en) | lobophorins N1-N3 and preparation method and application thereof | |
CN106905342B (en) | Structure of two active metabolites of streptomyces roseoflavus and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |